1. Home
  2. FLGT vs DCTH Comparison

FLGT vs DCTH Comparison

Compare FLGT & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • FLGT
  • DCTH
  • Stock Information
  • Founded
  • FLGT 2011
  • DCTH 1988
  • Country
  • FLGT United States
  • DCTH United States
  • Employees
  • FLGT N/A
  • DCTH N/A
  • Industry
  • FLGT Medical Specialities
  • DCTH Medical/Dental Instruments
  • Sector
  • FLGT Health Care
  • DCTH Health Care
  • Exchange
  • FLGT Nasdaq
  • DCTH Nasdaq
  • Market Cap
  • FLGT 639.0M
  • DCTH 630.4M
  • IPO Year
  • FLGT 2016
  • DCTH N/A
  • Fundamental
  • Price
  • FLGT $19.53
  • DCTH $13.85
  • Analyst Decision
  • FLGT Buy
  • DCTH Strong Buy
  • Analyst Count
  • FLGT 2
  • DCTH 4
  • Target Price
  • FLGT $24.00
  • DCTH $24.00
  • AVG Volume (30 Days)
  • FLGT 256.3K
  • DCTH 531.5K
  • Earning Date
  • FLGT 08-01-2025
  • DCTH 08-04-2025
  • Dividend Yield
  • FLGT N/A
  • DCTH N/A
  • EPS Growth
  • FLGT N/A
  • DCTH N/A
  • EPS
  • FLGT N/A
  • DCTH N/A
  • Revenue
  • FLGT $292,448,000.00
  • DCTH $53,850,000.00
  • Revenue This Year
  • FLGT $11.79
  • DCTH $155.42
  • Revenue Next Year
  • FLGT $10.45
  • DCTH $37.93
  • P/E Ratio
  • FLGT N/A
  • DCTH N/A
  • Revenue Growth
  • FLGT 1.71
  • DCTH 1068.87
  • 52 Week Low
  • FLGT $14.57
  • DCTH $7.17
  • 52 Week High
  • FLGT $25.11
  • DCTH $18.23
  • Technical
  • Relative Strength Index (RSI)
  • FLGT 40.94
  • DCTH 37.03
  • Support Level
  • FLGT $20.30
  • DCTH $15.72
  • Resistance Level
  • FLGT $21.07
  • DCTH $17.35
  • Average True Range (ATR)
  • FLGT 0.69
  • DCTH 0.74
  • MACD
  • FLGT -0.25
  • DCTH -0.40
  • Stochastic Oscillator
  • FLGT 1.15
  • DCTH 2.23

About FLGT Fulgent Genetics Inc.

Fulgent Genetics Inc is a technology company that focuses on genetic testing to provide physicians with clinically actionable diagnostic information. The company is engaged in laboratory services business and a therapeutic development business. The laboratory services business which generates key revenue includes, technical laboratory services and professional interpretation of laboratory results by licensed physicians. Its therapeutic development business is focused on developing drug candidates for treating a broad range of cancers. The geographical segments are the United States, which generates the vast majority of the revenue; and Foreign.

About DCTH Delcath Systems Inc.

Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.

Share on Social Networks: